Clinical Trial

Selective Coronary Revascularization in Peripheral Artery Disease Patients (SCOREPAD Trial)

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 16, 2024 (before its estimated February 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
The primary objective of this study is to determine whether among symptomatic Peripheral Arterial Disease (PAD) patients with no known Coronary Artery Disease (CAD) who had undergone lower-extremity revascularization, a strategy of best medical therapy (BMT) plus selective coronary revascularization based on FFRct assessment of lesion-specific coronary ischemia can reduce adverse cardiac events and improve survival compared to BMT alone. Lesion-specific coronary ischemia is defined as FFRCT ≤0.80 distal to stenosis in a major (≥2 mm) coronary artery with severe ischemia defined as FFRCT ≤0.75.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-02-01; most recent amendment 2024-02-15.
Status change: Not Yet Recruiting → Recruiting 2024-02-15
Trial Details
NCT Number NCT06250790
Lead Sponsor Pauls Stradins Clinical University Hospital
Conditions Peripheral Arterial Disease, Coronary Artery Disease
Enrollment 600 participants
Start Date 2024-02-15
Primary Completion 2026-02-15 (estimated)
Study Completion 2029-02-15 (estimated)
Updated on ClinicalTrials.gov 2024-02-16